Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer

In this phase II, multicentre trial, patients with metastatic breast cancer (MBC) were treated with a combination of gemcitabine, epirubicin and paclitaxel (GET). The primary objective of this study was to determine the tolerability and activity in terms of complete responce (CR) and overall respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Cappuzzo, F, Mazzoni, F, Gennari, A, Donati, S, Salvadori, B, Orlandini, C, Cetto, G L, Molino, A, Galligioni, E, Mansutti, M, Tumolo, S, Lucentini, A, Valduga, F, Bartolini, S, Crinò, L, Conte, P F
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395340/
https://www.ncbi.nlm.nih.gov/pubmed/14710202
http://dx.doi.org/10.1038/sj.bjc.6601518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395340/
https://www.ncbi.nlm.nih.gov/pubmed/14710202
http://dx.doi.org/10.1038/sj.bjc.6601518

Ejemplares similares